论文部分内容阅读
此文报道了初治的26例浆细胞白血病(PCL)并与664例多发性骨髓瘤(MM)进行了对比。从1982年1月～1996年12月共收治PCL26例,占同期690例MM的3.8％。其诊断标准为周围血中浆细胞(PCs)数明显增多,其绝对值>2×10~9/L,分类>20％。临床特征:与MM相比,PCL临床Ⅲ期者比例高(P=0.0093)。Bence Jones蛋白尿型更多见(31％)而IgA型较少(4％)。二组每日尿蛋白的排泄量、中数年龄、性别比、骨损害情况均类似。髓外受累在MM为4％而在PCL为23％(皮下结节,腹膜浆细胞瘤、脑膜浸润、胸壁肿块)。一些不利预后因素如β_2微球蛋白水平,LDH值,S期PCs比例,血清钙值,蛋白尿及肾功不全的发生率在PCL均明显增高。免疫分型:CD_(38)和CD_(138)抗原
This article reports the initial treatment of 26 plasma cell leukemia (PCL) and compared with 664 multiple myeloma (MM). From January 1982 to December 1996, 26 cases of PCL were treated, accounting for 3.8% of 690 cases of MM during the same period. The diagnostic criteria for peripheral blood plasma cells (PCs) increased significantly, the absolute value of> 2 × 10 ~ 9 / L, classification> 20%. Clinical features: Compared with MM, the proportion of PCL clinical stage III was high (P = 0.0093). Bence Jones had more proteinuria (31%) and IgA type (4%). Daily urinary protein excretion, median age, sex ratio, and bone damage were similar in the two groups. Extramedullary involvement was 4% in MM and 23% in PCL (subcutaneous nodules, peritoneal plasmacytomas, meningeal infiltrates, and chest wall mass). Some adverse prognostic factors such as β2-microglobulin, LDH, S-phase PCs, serum calcium, proteinuria, and renal insufficiency were all significantly higher in PCL. Immunophenotyping: CD_(38) and CD_(138) Antigens